Obermatt
See Similar Stocks →

Relmada Therapeutics

NAQ:RLMD · US75955J4022
PharmaceuticalsSmall

360° View

no current rank
Price/Sales—
Price/Earnings88
Price/Book25
Dividend Yield1
Revenue Growth—
Profit Growth49
Capital Growth97
TSR 52w98
Leverage76
Liquidity—
Refinancing36
Combined—
Analyst Opinions78
Pro Holdings47
Opinion Changes50
Market Pulse7

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees26
Websiterelmada.com
ISINUS75955J4022
Last UpdateApr 2, 2026
Index & Theme
UrologyNeurologyCentral Nervous SystemOncologyPsychedelic-Based TherapyBiotechnologyClinical TrialsPharmaceutical

Description

Relmada Therapeutics, Inc. (Relmada) is a clinical-stage biotechnology company. The company substantially redesigned its development programs following a comprehensive strategic review occasioned by disappointing interim analysis results in December…

Similar Stocks

The companies this stock is ranked against.

Compare Relmada Therapeutics with its peers
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Equillium
NAQ:EQ
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →